— Know what they know.
Not Investment Advice

TECH

Bio-Techne Corporation
1W: +1.2% 1M: -11.6% 3M: -9.7% YTD: -13.6% 1Y: -15.1% 3Y: -28.3% 5Y: -47.1%
$51.48
-0.11 (-0.21%)
After Hours: $52.16 (+0.68, +1.31%)
NASDAQ · Healthcare · Biotechnology · $8.1B · Alpha Radar Sell · Power 43
Smart Money Score
Bullish 100
Insider+$1.9M
Congress3 trades
ETF Holdings
Key Statistics
Market Cap$8.1B
52W Range46.01-72.16
Volume2,865,541
Avg Volume2,319,862
Beta1.48
Dividend$0.32
Analyst Ratings
18 Buy 7 Hold 0 Sell
Consensus Buy
Company Info
CEOKim Kelderman
Employees3,100
SectorHealthcare
IndustryBiotechnology
IPO Date1989-02-09
614 McKinley Place N.E.
Minneapolis, MN 55413
US
612 379 8854
About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Recent Insider Trades

NameTypeSharesPriceDate
Crouse Steven C. A-Award 2,387 2026-03-02
Crouse Steven C. A-Award 735 2026-03-02
Crouse Steven C. A-Award 1,911 $57.82 2026-03-02
Crouse Steven C. 0 2026-03-01
Crouse Steven C. 6,529 2026-03-01

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms